In addition to clinical trials, does data from a meta-analysis of retrospective cohort studies support the benefits of SGLT-2 inhibitors?
Read More »Evaluation of CVD/CKD Risks in Patients with Type 2 Diabetes
Despite being on first-line oral anti-diabetic drug therapy, the risk of developing CVD/CKD in patients with type 2 diabetes remains high.
Read More »Insight Into Turmeric Benefits in Diabetes and CVD
Examining how curcumin and other bioactive compounds in turmeric lower blood glucose.
Read More »Cost-effectiveness of SGLT2 Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction
Sodium-glucose cotransporter 2 (SGLT2) inhibitors were created to treat diabetes, but noted to ameliorate cardiovascular events.
Read More »Improve Cardiovascular Outcomes with DPP4 Inhibitors
DPP4 inhibitors may restore the normal functioning of vascular endothelium in patients who require insulin treatment.
Read More »Preventing Diabetes with Antihypertensives
Researchers showed that elevated blood pressure is a modifiable risk factor for new-onset type 2 diabetes.
Read More »Efpeglenatide Has Cardiovascular and Renal Benefit Outcomes in Type 2 Diabetes
Efpeglenatide has proven to significantly reduce several risk factors for cardiovascular and kidney disease.
Read More »Is Empagliflozin Safe and Effective for Patients with HFrEF and Low Blood Pressure?
The interaction between systolic blood pressure (SBP) and the effects of empagliflozin in patients with heart failure with reduced ejection fraction (HFrEF).
Read More »Canagliflozin vs. Sotagliflozin for Stroke Prevention in Patients with T2D and CKD
SGLT2 inhibitors are not created equal; patient-specific characteristics need to be considered for best efficacy.
Read More »The Impact of Body Weight Change on Cardiovascular Outcomes
Is weight loss always as beneficial as we think?
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.